JPRN-jRCT2031230525招募中Unknown
EPKINLY Subcutaneous Injection General use-results surveillance (All case) of relapsed or refractory large B-cell lymphoma and relapsed or refractory follicular lymphoma: OBSC3013-39D-E
Genmab K.K. Drug safety and pharmacovigilance0 个研究点目标入组 250 人开始时间: 2023年12月21日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable(—)
- 性别
- All
入选标准
- •All patients treated with EPKINLY
排除标准
- 未提供
研究者
相似试验
招募中
2 期
The efficacy and safety of subcutaneous injection of bortezomib combined with doxorubicin and dexamethasone for untreated multiple myeloma patients.multiple myelomaJPRN-UMIN000007803ational Hospital Organization Disaster Medical Center35
进行中(未招募)
不适用
Efficacy and Safety of subcutaneous administration of XM01 and Epoetin beta for treatment of anaemia in chronic renal failure patients not yet receiving dialysis. A multinational, multicentre, randomised, controlled, double-blind, parallel group phase II study.EUCTR2005-000140-85-HUBioGeneriX AG150
进行中(未招募)
不适用
Efficacy and Safety of subcutaneous administration of XM01 compared to Epoetin beta in anaemic chronic renal failure patients not yet receiving dialysis and in maintenance phase treatment with Epoetin beta. A multinational, multicentre, randomised, controlled, double-blind, comparative, parallel group Phase III study.anaemic chronic renal failure patients not yet receiving dialysisMedDRA version: 9Level: LLTClassification code 10009119EUCTR2005-000142-37-HUBioGeneriX AG255
招募中
不适用
HEMLIBRA Subcutaneous injection General Drug Use Surveillance(in Hemophilia A with Inhibitors).Hemophilia AJPRN-UMIN000032515Chugai Pharmaceutical Co. Ltd.100
已完成
4 期
Efficacy and Safety of Subcutaneous Administration of Lyophilized Powder of Alpha-Erythropoietin to Maintains Hemoglobin Concentrations among Hemodialysis PatientsAnemia associated with chronic kidney diseaseHemodialysisLyophilised powderErythropoietinAnemiaTCTR20161214001Phramongkutklao hospital and College of Medicine63
